

Corrigendum

Corrigendum to “High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana”

Naomi Hauser , Tanmay Sahai , Rocco Richards, and Todd Roberts

Department of Medicine, Roger Williams Medical Center, Boston University School of Medicine, Providence, RI 02908, USA

Correspondence should be addressed to Naomi Hauser; naomi.hauser@gmail.com

Received 6 August 2018; Accepted 14 August 2018; Published 6 September 2018

Copyright © 2018 Naomi Hauser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana” [1], there was an error in the units used in the dose of continuous infusion rate of tacrolimus. Accordingly, in the “Case Report” section, “He was started on a continuous tacrolimus infusion drip at 1.8 mg/kg on transplant Day –2 with a goal serum tacrolimus level of 8–12 ng/mL, which is our bone marrow transplant unit’s accepted therapeutic range. The patient’s blood tacrolimus level was measured and the drip was decreased to 1.5 mg/kg and then to 1.0 mg/kg due to levels being persistently just above target” should be corrected to “He was started on a continuous tacrolimus infusion drip at 1.8 mg/24 hours on transplant Day –2 with a goal serum tacrolimus level of 8–12 ng/mL, which is our bone marrow transplant unit’s accepted therapeutic range. The patient’s blood tacrolimus level was measured and the drip was decreased to 1.5 mg/24 hours and then to 1.0 mg/24 hours due to levels being persistently just above target.”

References

- [1] N. Hauser, T. Sahai, R. Richards, and T. Roberts, “High on cannabis and calcineurin inhibitors: a word of warning in an era of legalized marijuana,” *Case Reports in Transplantation*, vol. 2016, Article ID 4028492, 3 pages, 2016.